Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
ABT Abbott Laboratories	$132.76 +1.1%	$130.36	$110.86 ▼ $141.23	$231.06B	0.69	6.65 million shs	5.40 million shs
BMY Bristol Myers Squibb	$46.30 -0.1%	$47.07	$42.96 ▼ $63.33	$94.24B	0.35	12.93 million shs	9.05 million shs
LLY Eli Lilly and Company	$763.59 +2.1%	$740.54	$623.78 ▼ $939.86	$722.71B	0.47	4.10 million shs	3.88 million shs
NVO Novo Nordisk A/S	$57.19 +2.8%	$57.69	$45.05 ▼ $135.20	$255.35B	0.66	11.87 million shs	17.05 million shs

Options Trading Made Easy - Download Now

Learn the basics of options trading and how to use them to boost returns and manage risk with this free report from MarketBeat. Click the link below to get your free copy.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
ABT Abbott Laboratories	-1.88%	-0.66%	-0.20%	-0.59%	+12.89%
BMY Bristol Myers Squibb	+0.26%	-0.74%	-4.36%	-1.92%	-5.68%
LLY Eli Lilly and Company	-0.88%	+1.31%	+6.66%	-5.48%	-18.99%
NVO Novo Nordisk A/S	+1.24%	+2.43%	+6.08%	-25.22%	-59.40%

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
ABT Abbott Laboratories	$132.76 +1.1%	$130.36	$110.86 ▼ $141.23	$231.06B	0.69	6.65 million shs	5.40 million shs
BMY Bristol Myers Squibb	$46.30 -0.1%	$47.07	$42.96 ▼ $63.33	$94.24B	0.35	12.93 million shs	9.05 million shs
LLY Eli Lilly and Company	$763.59 +2.1%	$740.54	$623.78 ▼ $939.86	$722.71B	0.47	4.10 million shs	3.88 million shs
NVO Novo Nordisk A/S	$57.19 +2.8%	$57.69	$45.05 ▼ $135.20	$255.35B	0.66	11.87 million shs	17.05 million shs

Options Trading Made Easy - Download Now

Learn the basics of options trading and how to use them to boost returns and manage risk with this free report from MarketBeat. Click the link below to get your free copy.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
ABT Abbott Laboratories	-1.88%	-0.66%	-0.20%	-0.59%	+12.89%
BMY Bristol Myers Squibb	+0.26%	-0.74%	-4.36%	-1.92%	-5.68%
LLY Eli Lilly and Company	-0.88%	+1.31%	+6.66%	-5.48%	-18.99%
NVO Novo Nordisk A/S	+1.24%	+2.43%	+6.08%	-25.22%	-59.40%

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
ABT Abbott Laboratories	2.91	Moderate Buy	$144.47	8.82% Upside
BMY Bristol Myers Squibb	2.24	Hold	$56.38	21.76% Upside
LLY Eli Lilly and Company	2.70	Moderate Buy	$947.39	24.07% Upside
NVO Novo Nordisk A/S	2.24	Hold	$81.00	41.63% Upside

Current Analyst Ratings Breakdown

Latest NVO, LLY, ABT, and BMY Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
9/16/2025	LLY Eli Lilly and Company	JPMorgan Chase & Co. Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Lower Price Target	Overweight	$1,100.00 ➝ $1,050.00
9/16/2025	NVO Novo Nordisk A/S	Rothschild & Co Redburn Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Upgrade	Neutral ➝ Buy
9/9/2025	NVO Novo Nordisk A/S	Sanford C. Bernstein Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Upgrade	Market Perform ➝ Outperform
8/27/2025	LLY Eli Lilly and Company	HSBC Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Upgrade	Reduce ➝ Hold	$675.00 ➝ $700.00
8/27/2025	LLY Eli Lilly and Company	Hsbc Global Res Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Upgrade	Moderate Sell ➝ Hold
8/22/2025	NVO Novo Nordisk A/S	Dbs Bank Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Upgrade	Strong Sell ➝ Hold
8/20/2025	NVO Novo Nordisk A/S	Zacks Research Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Downgrade	Hold ➝ Strong Sell
8/19/2025	NVO Novo Nordisk A/S	TD Cowen Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Lower Price Target	Buy	$105.00 ➝ $70.00
8/17/2025	LLY Eli Lilly and Company	Daiwa Capital Markets Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Downgrade	Outperform ➝ Neutral	$700.00
8/17/2025	LLY Eli Lilly and Company	Daiwa America Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Downgrade	Strong-Buy ➝ Hold
8/14/2025	LLY Eli Lilly and Company	DZ Bank Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Upgrade	Hold ➝ Strong-Buy

(Data available from 9/16/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
ABT Abbott Laboratories	$41.95B	5.51	$6.54 per share	20.31	$27.62 per share	4.81
BMY Bristol Myers Squibb	$48.30B	1.95	$5.90 per share	7.85	$8.08 per share	5.73
LLY Eli Lilly and Company	$45.04B	16.04	$14.39 per share	53.07	$15.03 per share	50.80
NVO Novo Nordisk A/S	$311.94B	0.82	$4.07 per share	14.06	$4.66 per share	12.27

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
ABT Abbott Laboratories	$13.40B	$7.98	16.64	23.17	2.54	32.43%	18.32%	10.71%	10/15/2025 (Estimated)
BMY Bristol Myers Squibb	-$8.95B	$2.48	18.67	7.60	2.36	10.58%	80.04%	14.69%	10/30/2025 (Estimated)
LLY Eli Lilly and Company	$10.59B	$15.30	49.91	24.54	1.05	25.91%	92.72%	16.89%	10/29/2025 (Estimated)
NVO Novo Nordisk A/S	$14.64B	$3.64	15.71	12.27	2.08	35.60%	78.64%	24.51%	11/5/2025 (Estimated)

Latest NVO, LLY, ABT, and BMY Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue
8/7/2025	Q2 2025	LLY Eli Lilly and Company	$5.59	$6.31	+$0.72	$6.29	$14.40 billion	$15.56 billion
8/6/2025	Q2 2025	NVO Novo Nordisk A/S	$0.93	$0.97	+$0.04	$0.91	$77.51 billion	$11.69 billion
7/31/2025	Q2 2025	BMY Bristol Myers Squibb	$1.07	$1.46	+$0.39	$0.64	$11.32 billion	$12.27 billion
7/17/2025	Q2 2025	ABT Abbott Laboratories	$1.26	$1.26	N/A	$1.01	$11.01 billion	$11.14 billion

Compare Dividends

Company	Annual Payout	Dividend Yield	3-Year Dividend Growth	Payout Ratio	Years of Consecutive Growth
ABT Abbott Laboratories	$2.36	1.78%	N/A	29.57%	54 Years
BMY Bristol Myers Squibb	$2.48	5.36%	N/A	100.00%	17 Years
LLY Eli Lilly and Company	$6.00	0.79%	N/A	39.22%	11 Years
NVO Novo Nordisk A/S	$0.82	1.43%	N/A	22.53%	N/A

Latest NVO, LLY, ABT, and BMY Dividends

Announcement	Company	Period	Amount	Yield	Ex-Dividend Date	Record Date	Payable Date
6/23/2025	LLY Eli Lilly and Company	quarterly	$1.50	0.78%	8/15/2025	8/15/2025	9/10/2025
8/6/2025	NVO Novo Nordisk A/S	semi-annual	$0.4119	2.4%	8/18/2025	8/18/2025	8/26/2025
6/17/2025	BMY Bristol Myers Squibb	quarterly	$0.62	5.25%	7/3/2025	7/3/2025	8/1/2025

(Data available from 1/1/2013 forward)

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
ABT Abbott Laboratories	0.25	1.82	1.30
BMY Bristol Myers Squibb	2.54	1.21	1.11
LLY Eli Lilly and Company	1.86	1.28	1.00
NVO Novo Nordisk A/S	0.52	0.78	0.56

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
ABT Abbott Laboratories	75.18%
BMY Bristol Myers Squibb	76.41%
LLY Eli Lilly and Company	82.53%
NVO Novo Nordisk A/S	11.54%

Insider Ownership

Company	Insider Ownership
ABT Abbott Laboratories	0.46%
BMY Bristol Myers Squibb	0.07%
LLY Eli Lilly and Company	0.14%
NVO Novo Nordisk A/S	0.07%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
ABT Abbott Laboratories	114,000	1.74 billion	1.73 billion	Optionable
BMY Bristol Myers Squibb	34,100	2.04 billion	2.03 billion	Optionable
LLY Eli Lilly and Company	47,000	946.46 million	945.13 million	Optionable
NVO Novo Nordisk A/S	77,349	4.47 billion	4.46 billion	Optionable

NVO, LLY, ABT, and BMY Headlines

Recent News About These Companies

Class Action Filed Against Novo Nordisk A/S (NVO) Seeking Recovery for Investors – Contact Levi & Korsinsky

3 hours ago | globenewswire.com

Novo Nordisk A/S Investors: Please contact the Portnoy Law Firm to recover your losses; March 25, 2025 Deadline to file Lead Plaintiff Motion

4 hours ago | globenewswire.com

Novo Nordisk A/S (NVO): A Bull Case Theory

September 16 at 12:31 PM | insidermonkey.com

DEADLINE ALERT for SOC, LMT, NVO, and LINE: The Law Offices of Frank R. Cruz Reminds Investors of Class Actions on Behalf of Shareholders

September 16 at 11:43 AM | globenewswire.com

Novo Nordisk Stock Rises on Trial Results for Cagrilintide Obesity Treatment

September 16 at 10:50 AM | investopedia.com

Is Novo Nordisk TV Ad Buying Fueling Stock Price?

September 16 at 10:49 AM | seeitmarket.comS

Novo Nordisk shares higher on positive Phase 3 trial results for obesity drug Cagrilintide

September 16 at 9:59 AM | proactiveinvestors.com

Will Rybelsus' Updated EU Label Propel Fresh Growth Potential for NVO?

September 16 at 9:56 AM | zacks.com

Levi & Korsinsky Notifies Shareholders of Novo Nordisk A/S(NVO) of a Class Action Lawsuit and an Upcoming Deadline

September 16 at 8:45 AM | prnewswire.com

Novo Nordisk A/S (NYSE:NVO) Rating Increased to Buy at Rothschild & Co Redburn

September 16 at 8:23 AM | marketbeat.com

Novo Nordisk to test weight-loss drugs in broader range of obesity-linked conditions

September 16 at 7:54 AM | reuters.com

Jim Cramer Discusses Novo Nordisk A/S (NVO) And CVS

September 16 at 7:33 AM | insidermonkey.com

Novo Nordisk flags drug trial promise amid hunt for next weight-loss blockbuster

September 16 at 7:26 AM | cnbc.com

Jim Cramer Discusses Novo Nordisk A/S (NVO) And CVS

September 16 at 7:10 AM | finance.yahoo.com

Novo Nordisk A/S $NVO Shares Acquired by Fiduciary Alliance LLC

September 16 at 6:49 AM | marketbeat.com

Novo Nordisk A/S $NVO Shares Acquired by Bank of New Hampshire

September 16 at 6:48 AM | marketbeat.com

Norman Fields Gottscho Capital Management LLC Sells 33,275 Shares of Novo Nordisk A/S $NVO

September 16 at 6:31 AM | marketbeat.com

Novo Nordisk presents phase 3 data for next-generation amylin cagrilintide, leading to advancement into dedicated clinical programme

September 16 at 6:00 AM | globenewswire.com

Novo Nordisk's Wegovy Helps Suppress Thoughts About Food, Study Suggests

September 16 at 2:57 AM | wsj.com

Novo Nordisk A/S Sued for Securities Law Violations – Investors Should Contact The Gross Law Firm Before September 30, 2025 to Discuss Your Rights – NVO

September 15 at 4:00 PM | globenewswire.com

EU approves update for Novo Nordisk’s oral semaglutide in cardio risk reduction

September 15 at 1:27 PM | thepharmaletter.comT

New MarketBeat Followers Over Time

Media Sentiment Over Time

Top Headlines

View All

NVO, LLY, ABT, and BMY Company Descriptions

Abbott Laboratories NYSE:ABT

$132.76 +1.43 (+1.09%)

Closing price 03:59 PM Eastern

Extended Trading

$133.22 +0.46 (+0.35%)

As of 07:55 PM Eastern

Abbott Laboratories, together with its subsidiaries, discovers, develops, manufactures, and sells health care products worldwide. It operates in four segments: Established Pharmaceutical Products, Diagnostic Products, Nutritional Products, and Medical Devices. The company provides generic pharmaceuticals for the treatment of pancreatic exocrine insufficiency, irritable bowel syndrome or biliary spasm, intrahepatic cholestasis or depressive symptoms, gynecological disorder, hormone replacement therapy, dyslipidemia, hypertension, hypothyroidism, Ménière's disease and vestibular vertigo, pain, fever, inflammation, and migraine, as well as provides anti-infective clarithromycin, influenza vaccine, and products to regulate physiological rhythm of the colon. It also offers laboratory and transfusion medicine systems in the areas of immunoassay, clinical chemistry, hematology, and transfusion; molecular diagnostics polymerase chain reaction instrument systems that automate the extraction, purification, and preparation of DNA and RNA from patient samples, and detect and measure infectious agents; point of care systems; cartridges for testing blood gas, chemistry, electrolytes, coagulation, and immunoassay; rapid diagnostics lateral flow testing products; molecular point-of-care testing for HIV, SARS-CoV-2, influenza A and B, RSV, and strep A; cardiometabolic test systems; drug and alcohol test, and remote patient monitoring and consumer self-test systems; and informatics and automation solutions for laboratories. In addition, the company provides pediatric and adult nutritional products; rhythm management, electrophysiology, heart failure, vascular, and structural heart devices for the treatment of cardiovascular diseases; diabetes care products, such as glucose and blood glucose monitoring systems; and neuromodulation devices for the management of chronic pain and movement disorders. Abbott Laboratories was founded in 1888 and is based in North Chicago, Illinois.

Bristol Myers Squibb NYSE:BMY

$46.30 -0.05 (-0.11%)

Closing price 03:59 PM Eastern

Extended Trading

$46.27 -0.03 (-0.06%)

As of 07:59 PM Eastern

Bristol-Myers Squibb Company discovers, develops, licenses, manufactures, markets, distributes, and sells biopharmaceutical products worldwide. It offers products for hematology, oncology, cardiovascular, immunology, fibrotic, and neuroscience diseases. The company's products include Eliquis for reduction in risk of stroke/systemic embolism in non-valvular atrial fibrillation, and for the treatment of DVT/PE; Opdivo for various anti-cancer indications, including bladder, blood, CRC, head and neck, RCC, HCC, lung, melanoma, MPM, stomach and esophageal cancer; Pomalyst/Imnovid for multiple myeloma; Orencia for active rheumatoid arthritis and psoriatic arthritis; and Sprycel for the treatment of Philadelphia chromosome-positive chronic myeloid leukemia. It also provides Yervoy for the treatment of patients with unresectable or metastatic melanoma; Empliciti for the treatment of multiple myeloma; Abecma for the treatment of relapsed or refractory multiple myeloma; Reblozyl for the treatment of anemia; Opdualag for the treatment of unresectable or metastatic melanoma; and Zeposia to treat relapsing forms of multiple sclerosis. In addition, the company offers Breyanzi for the treatment of relapsed or refractory large B-cell lymphoma; Onureg for the treatment of AML; Inrebic for the treatment of myelofibrosis; Camzyos for the treatment of symptomatic obstructive HCM to enhance functional capacity and symptom; Sotyktu for the treatment of moderate-to-severe plaque psoriasis; Augtyro for the treatment of locally advanced or metastatic ROS1-positive NSCLC; Revlimid, an oral immunomodulatory drug for the treatment of multiple myeloma; and Abraxane to treat breast cancer, NSCLC and pancreatic cancer. It sells products to wholesalers, distributors, pharmacies, retailers, hospitals, clinics, and government agencies. The company was formerly known as Bristol-Myers Company. Bristol-Myers Squibb Company was founded in 1887 and is headquartered in Princeton, New Jersey.

Eli Lilly and Company NYSE:LLY

$763.59 +15.40 (+2.06%)

Closing price 03:59 PM Eastern

Extended Trading

$763.55 -0.04 (-0.01%)

As of 07:59 PM Eastern

Eli Lilly and Company discovers, develops, and markets human pharmaceuticals worldwide. The company offers Basaglar, Humalog, Humalog Mix 75/25, Humalog U-100, Humalog U-200, Humalog Mix 50/50, insulin lispro, insulin lispro protamine, insulin lispro mix 75/25, Humulin, Humulin 70/30, Humulin N, Humulin R, and Humulin U-500 for diabetes; Jardiance, Mounjaro, and Trulicity for type 2 diabetes; and Zepbound for obesity. It also provides oncology products, including Alimta, Cyramza, Erbitux, Jaypirca, Retevmo, Tyvyt, and Verzenio. In addition, the company offers Olumiant for rheumatoid arthritis, atopic dermatitis, severe alopecia areata, and COVID-19; Taltz for plaque psoriasis, psoriatic arthritis, ankylosing spondylitis, and non-radiographic axial spondylarthritis; Omvoh for ulcerative colitis; Cymbalta for depressive disorder, diabetic peripheral neuropathic pain, generalized anxiety disorder, fibromyalgia, and chronic musculoskeletal pain; Ebglyss for severe atopic dermatitis; and Emgality for migraine prevention and episodic cluster headache. Further, it provides Cialis for erectile dysfunction and benign prostatic hyperplasia; and Forteo for osteoporosis. It has collaborations with Incyte Corporation; Boehringer Ingelheim Pharmaceuticals, Inc.; F. Hoffmann-La Roche Ltd and Genentech, Inc.; Biologics, Inc., AbCellera Biologics Inc.; and Chugai Pharmaceutical Co., Ltd. The company was founded in 1876 and is headquartered in Indianapolis, Indiana.

Novo Nordisk A/S NYSE:NVO

$57.19 +1.57 (+2.82%)

Closing price 03:59 PM Eastern

Extended Trading

$57.46 +0.27 (+0.46%)

As of 07:59 PM Eastern

Novo Nordisk A/S, together with its subsidiaries, engages in the research and development, manufacture, and distribution of pharmaceutical products in Europe, the Middle East, Africa, Mainland China, Hong Kong, Taiwan, North America, and internationally. It operates in two segments, Diabetes and Obesity Care, and Rare Disease. The Diabetes and Obesity care segment provides products for diabetes, obesity, cardiovascular, and other emerging therapy areas. The Rare Disease segment offers products in the areas of rare blood disorders, rare endocrine disorders, and hormone replacement therapy. The company also provides insulin pens, growth hormone pens, and injection needles. In addition, it offers smart solutions for diabetes treatment, such as smart insulin pens and Dose Check, an insulin dose guidance application. The company has a collaboration agreement with Aspen Pharmaceuticals to produce insulin products; and with Korro Bio, Inc. for the discovery and development of new genetic medicines to treat cardiometabolic diseases. Novo Nordisk A/S was founded in 1923 and is headquartered in Bagsvaerd, Denmark.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time

Compare Price & Volume

Compare Price Performance

Compare Price & Volume

Compare Price Performance

Compare Analyst Forecasts

Current Analyst Ratings Breakdown

Latest NVO, LLY, ABT, and BMY Analyst Ratings

Compare Sales & Book Value

Compare Profitability & Earnings

Latest NVO, LLY, ABT, and BMY Earnings

Compare Dividends

Latest NVO, LLY, ABT, and BMY Dividends

Compare Debt

Compare Ownership

Institutional Ownership

Insider Ownership

Compare Miscellaneous Stats

NVO, LLY, ABT, and BMY Headlines

Recent News About These Companies

New MarketBeat Followers Over Time

Media Sentiment Over Time

Top Headlines

NVO, LLY, ABT, and BMY Company Descriptions

Abbott Laboratories NYSE:ABT

Bristol Myers Squibb NYSE:BMY

Eli Lilly and Company NYSE:LLY

Novo Nordisk A/S NYSE:NVO

More Stock Comparisions from MarketBeat

Stock Comparison Ideas (A-K)

Stock Comparison Ideas (L-Z)

More Stock Ideas from MarketBeat

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools